ResearchMoz

Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals

Publisher Name » GlobalData
Published Date » 2012-05-21
No. Of Pages » 64


GlobalData's Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2012. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena. 
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 7
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2012 7
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2012 9
2.2.1 Nestle To Acquire Pfizer Nutrition From Pfizer For $11.9 Billion 9
2.2.2 Watson Pharma To Acquire Swiss Drug Maker Actavis Group For Up To $5.9 Billion 9
2.2.3 SXC Health Solutions To Acquire Catalyst Health Solutions For $4.4 Billion 9
2.2.4 Hologic To Acquire Gen-Probe, Diagnostic Test Maker, For $3.7 Billion 10
2.2.5 AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.3 Billion 10
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, April 2012 11

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 12
3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2012 12
3.1.1 Top M&A Deals in April 2012 13
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2011-April 2012 14
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2012 15
3.2.1 Top Equity Offering Deals in April 2012 16
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2011 - April 2012 17
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2012 18
3.3.1 Top PE/VC Deals in April 2012 19
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2012 20
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2012 21
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2011 - April 2012 22
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2011 - April 2012 23

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2012 24
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2012 24
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2011 - April 2012 25
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 26
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2012 27
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), November 2011 - April 2012 29
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 30

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2012 31
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2012 31
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2012 33
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2012 34
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2012 34
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2011 - April 2012 35
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2011 - April 2012 36
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2011 - April 2012 37
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2011 - April 2012 38

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 39
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2012 39
6.1.1 Oncology - Deals of the Month 40
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2012 41
6.2.1 Central Nervous System - Deals of the Month 42
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2012 43
6.3.1 Infectious Diseases - Deals of the Month 44
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2012 45
6.4.1 Immunology - Deals of the Month 46
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, April 2012 47
6.5.1 Metabolic Disorders - Deals of the Month 48
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, April 2012 49
6.6.1 Gastrointestinal - Deals of the Month 50
6.7 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2012 51
6.7.1 Cardiovascular - Deals of the Month 52

7 Deal Summary by Geography 53
7.1 Pharmaceuticals & Healthcare, North America Deals, April 2012 53
7.1.1 North America - Deals of the Month 54
7.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2012 55
7.2.1 Europe - Deals of the Month 56
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2012 57
7.3.1 Asia-Pacific - Deals of the Month 58
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2012 59
7.4.1 Rest of the World - Deals of the Month 60

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 61
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2011 - April 2012 61
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2011 - April 2012 62

9 Further Information 63
9.1 Methodology 63
9.2 About GlobalData 63
9.3 Contact Us 64
9.4 Disclosure information 64
9.5 Disclaimer 64

List of Tables

 
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 8
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2012 9
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2012 11
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2012 13
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 14
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 15
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2012 16
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 17
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 18
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2012 19
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2011 - April 2012 20
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2012 21
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 22
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2011 - April 2012 23
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 24
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 25
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 26
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2012 27
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 29
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2011 - April 2012 30
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 32
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 33
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, April 2012 34
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2012 34
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), November 2011 - April 2012 35
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2012 36
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 37
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 38
Table 31: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 40
Table 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 41
Table 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 43
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 45
Table 35: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 47
Table 36: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 49
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 51
Table 38: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 54
Table 39: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 55
Table 40: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 57
Table 41: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 59
Table 42: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 61
Table 43: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 62

List of Figures

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 7
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),April 2012 11
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 12
Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 14
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 15
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 17
Figure 7: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 18
Figure 8: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 20
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), April 2012 21
Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 22
Figure 11: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 24
Figure 12: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 25
Figure 13: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 26
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 29
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 30
Figure 17: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 31
Figure 18: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 33
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), November 2011 - April 2012 37
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 38
Figure 23: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 39
Figure 24: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 41
Figure 25: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 43
Figure 26: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 45
Figure 27: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 47
Figure 28: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 49
Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 51
Figure 30: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 53
Figure 31: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 55
Figure 32: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 57
Figure 33: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 59
Figure 34: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 61
Figure 35: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 62

Upcoming Reports:

Mexico Ophthalmic Devices Market: Industry Size, Market Share, Trends,Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
SCOPE OF THE REPORT This report is an effort to identify factors, which will be the driving force behind the ophthalmic devices market and sub-markets in the next six years. This report is specially designed to estimate and analyze the demand and performance of Mexican ophthalmic devices market. The report provides extensive analysis of the ophthalmic devices industry, current market trends, industry drivers and challenges for better understanding of the ophthalmic devices market structure. The report has segregated the ophthalmic devices industry in terms of...
Nanotechnology in Medical Equipment Market - Global Industry Analysis, Market Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Nanotechnology has tremendous potential to reform the healthcare industry. It is expected that incorporation of nanotechnology in various applications of healthcare will be the major phenomenon to watch in the next decade. Thus nanotechnology in healthcare offers substantial opportunities to revolutionize the field of diagnosis, prevention and treatment of diseases. Increase in prevalence of chronic diseases, rising awareness about preventive measures of healthcare and large scale development in nanotechnology are the major drivers of this market. Incorporation of...
Nanocoatings Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Properties like anti-corrosion, flame retardant, UV stability, gloss retention, etc. are enhanced significantly with the use of nanostructured materials. Nanocoatings are majorly used in construction for exterior protection, military and defense for anti-corrosion coatings of military vehicles, household cleansing, and automotives. Defense Industry is one of the biggest markets for Nanocoatings technology where anti-corrosive coatings are increasingly applied. These coatings are driving revenues in the oil and gas industry for protective surfaces in pipelines and harsh...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...